Compare Abeona Therapeutics Inc (ABEO) vs Cognizant Technology Solutions Corp (CTSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Cognizant Technology Solutions Corp — how do they compare? Abeona Therapeutics Inc trades at $6.7 (market cap $373.32M), while Cognizant Technology Solutions Corp trades at $42.61 (market cap $20.78B). The key difference: Cognizant Technology Solutions Corp is far larger — about 55.7× Abeona Therapeutics Inc's market cap, and Cognizant Technology Solutions Corp pays a 3% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CTSH | |
|---|---|---|
Market Cap | $373.32M | $20.78B |
Sector | Health | Technology |
52-Week High | $7.23 | $86.70 |
52-Week Low | $4.17 | $38.73 |
Enterprise Value | $228.22M | $20.36B |
Dividend Yield | — | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Cognizant Technology Solutions (CTSH) trades at $43.94, up 4.64% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 8.97 and net margin of 10.41%, supported by $21.11B revenue in 2025. Recent news highlights AI partnerships with Google Cloud and OpenAI, positioning CTSH for growth in enterprise AI solutions.
Outlook remains positive with a consensus price target of $67.58, implying 54% upside, though near-term risks include soft IT demand and margin pressures. Institutional sentiment is mixed with 43% buy ratings, but the valuation discount and AI expansion present a compelling opportunity for long-term investors amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →
